Morphological changes and differentially expressed efflux pump genes in Mycobacterium tuberculosis exposed to a rifampicin and verapamil combination

• Autor(a) principal: Caleffi-Ferracioli, Katiany R.
• Data de Publicação: 2016
• Outros Autores: Amaral, Renata Claro R., Demitto, Fernanda O., Maltempe, Flaviane G., Canezin, Pedro Henrique, Scodro, Regiane B. L., Nakamura, Celso V., Leite, Clarice Queico F. [UNESP], Siqueira, Vera Lucia D., Cardoso, Rosilene F.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNESP
• Texto Completo: http://dx.doi.org/10.1016/j.tube.2015.12.010; http://hdl.handle.net/11449/161372
• topic: Mycobacterium tuberculosis; Efflux pump; Morphological changes; Gene expression; Drug combinations

The aim of the present study was to (i) evaluate the in vitro action of rifampicin (RIF), ethambutol or isoniazid with efflux pumps inhibitors (EPIs) in Mycobacterium tuberculosis (Mtb) H(37)Rv and (ii) evaluate the morphological and efflux pumps (EPs) transcriptional changes by the action of rifampicin + verapamil combination (RIF + VP). The minimal inhibitory concentration and synergic effect of drug combinations were determined by Resazurin Microtiter Plate Assay and Resazurin Drugs Combination Microtiter Assay, respectively. VP showed greater capacity of ethidium bromide accumulation and RIF + VP had the lower fractional inhibitory concentration index. The RIF + VP exerted a similar reduction of viable cell counts to RIF by time kill curve, but decreases in the expression of EPs genes were observed by Real time PCR at 72 h of RIF + VP exposure. Accumulative morphological changes (wrinkled and rounding) caused by each drug were observed by scanning electron microscopy after RIF + VP exposure. The downexpression of EPs related genes exposed to RIF + VP, suggest an effective inhibitory activity of VP in Mtb H(37)Rv. The role of EPs and the use of EPIs open up a powerful approach and the RIF + VP combination should be studied in Mtb more thoroughly. (c) 2016 Elsevier Ltd. All rights reserved.